Rajahmundry Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.30 M
- Revenue Growth -23.23%
- Profit Growth -285.39%
- Ebitda -81.71%
- Net Worth -4.06%
- Total Assets -56.09%
About Rajahmundry Pharmaceuticals
Rajahmundry Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 November 2013 and has a history of 11 years and three months. Its registered office is in Rajahmundry, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹2.30 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chittuluri Rao, Grandhi Kameswara, Ramaji Pendem, and One other member serve as directors at the Company.
Company Details
-
Location
Rajahmundry, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233AP2013PTC090933
-
Company No.
090933
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Nov 2013
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Rajahmundry Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chittuluri Rao
|
Director | 11-Nov-2013 | Current |
|
Grandhi Kameswara
|
Director | 11-Nov-2013 | Current |
|
Ramaji Pendem
|
Director | 11-Nov-2013 | Current |
|
Pilla Bala
|
Director | 11-Nov-2013 | Current |
Financial Performance of Rajahmundry Pharmaceuticals.
Rajahmundry Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 23.23% decrease. The company also saw a substantial fall in profitability, with a 285.39% decrease in profit. The company's net worth dipped by a decrease of 4.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rajahmundry Pharmaceuticals?
In 2023, Rajahmundry Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹2.30 M
Charges Breakdown by Lending Institutions
- The Karur Vysya Bank Limited : 0.23 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 May 2014 | The Karur Vysya Bank Limited | ₹2.30 M | Satisfied |
How Many Employees Work at Rajahmundry Pharmaceuticals?
Unlock and access historical data on people associated with Rajahmundry Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rajahmundry Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rajahmundry Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
